ArticleJournal of health, population, and nutrition2026
Residual inflammatory risk as a predictor of cardiometabolic multi-morbidity: results from three prospective cohorts.
Article in Journal of health, population, and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond lipids: a precision prevention blueprint for China's residual risk.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation and its dynamic changes are intricately linked to cardiovascular diseases. This research aimed to explore the predictive significance of residual inflammatory risk (RIR) in evaluating the likelihood of developing cardiometabolic multi-morbidity (CMM).
methodsData were sourced from the China Health and Retirement Longitudinal Study (CHARLS), the Health and Retirement Study (HRS) and panzhihua central hospital. Inflammation status was assessed using at least two high-sensitivity C-reactive protein (hsCRP) measurements taken at baseline and follow-up, with a minimum interval of four weeks. High RIR was characterized by an hsCRP level exceeding 2 mg/L. Participants were categorized into four groups: persistent high RIR, increased RIR (initially low, subsequently high hsCRP), attenuated RIR (initially high, subsequently low hsCRP), and persistent low RIR. Multivariable Cox proportional hazards regression and subgroup analyses were employed to examine the relationship between RIR and CMM.
resultsThe study included 5,572 participants from the CHARLS (56.26% female, mean age 57.87 years), 3,856 participants from the HRS (60.35% female, mean age 65.74 years), and 2,446 participants from the panzhihua central hospital (54.17% female, mean age 58.65 years). Utilizing Cox proportional hazards regression, participants with persistent high RIR exhibited a significant association with an increased risk of developing CMM compared to those with persistent low RIR (CHARLS: HR = 2.2, 95% CI = 1.79-2.69, P < 0.001; HRS: HR = 1.79, 95% CI = 1.47-2.18, P < 0.001; panzhihua cohort: HR = 3.97, 95% CI = 2.52-6.27, P < 0.001). This association persisted after comprehensive adjustment for potential confounders (CHARLS: HR = 1.81, 95% CI = 1.47-2.23, P < 0.001; HRS: HR = 1.69, 95% CI = 1.38-2.08, P < 0.001; panzhihua cohort: HR = 3.74, 95% CI = 2.34-5.99, P < 0.001). Subgroup analyses further confirmed the robustness of the association between persistent high RIR and CMM across all examined subgroups.
conclusionPersistent high RIR was correlated with an increased risk of CMM. Future research is needed to determine whether anti-inflammatory strategies targeting RIR reduction could mitigate CMM risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.